External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Aarti Drugs’ reported Q4FY23 results stood above our expectations, led by an increase in volume uptick and improvement in the operating profitability due to operating leverage.</li><li>Reported Revenue at Rs 742 Cr grew by 7.0% YoY, led by the API segment which grew by 10% YoY.</li><li>There has been a good pick-up in the API volume offtake from Jan’23 and onwards across the API industry which is expected to remain higher in the upcoming quarters.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Aarti Drugs’ reported Q4FY23 results stood above our expectations, led by an increase in volume uptick and improvement in the operating profitability due to operating leverage.Reported Revenue at Rs 742 Cr grew by 7.0% YoY, led by the API segment which grew by 10% YoY.There has been a good pick-up in the API volume offtake from Jan’23 and onwards across the API industry which is expected to remain higher in the upcoming quarters.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aarti Drugs Ltd - API Volumes Expected to Pick Up in the Upcoming Quarters